ReviewCurrent opinion in oncology1999
Developing recombinant and synthetic vaccines for the treatment of melanoma.
Review in Current opinion in oncology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 61 citations in OpenAlex.
- Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.Cancer gene therapy · 2003Trial
- Calcaneal melanoma; our rare case and review of the literature.The Indian journal of surgery · 2013Article
- Immune surveillance in the skin: mechanisms and clinical consequences.Nature reviews. Immunology · 2004Review
- Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.Gene therapy · 2003Article
- Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.British journal of cancer · 2003Article
- Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.The American journal of pathology · 2002Article
- Gene-based cancer vaccines: an ex vivo approach.Leukemia · 2001Review
- Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18.Immunology · 2001Article
- Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.Current opinion in immunology · 2000Review
- Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.Journal of immunology (Baltimore, Md. : 1950) · 2000Article
- The future of interleukin-2: enhancing therapeutic anticancer vaccines.The cancer journal from Scientific American · 2000Review
- Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".Critical reviews in immunology · 2000Review
- Review
- Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.Journal of immunology (Baltimore, Md. : 1950) · 1999Article
- Hierarchy, tolerance, and dominance in the antitumor T-cell response.Journal of immunotherapy (Hagerstown, Md. : 1997)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.